PMD – New Name and Ticker Symbol; Irish Minister To Attend Bell-Ringing Ceremony

2024-01-16

并购上市批准

STOCKHOLM, SWEDEN / ACCESSWIRE / January 16, 2024 / Promore Pharma (STO:PROMO) (FRA:8T0) Following the reverse acquisition of Promore Pharma AB and change of name of the company from Promore Pharma AB to PMD Device Solutions AB ("PMD" or the "Company") the Company's ticker symbol will change from PROMO to PMDS with effect from 17 January 2024. To mark the completion of the reverse acquisition of the Company on 29 December 2023, the CEO and Founder of PMD, Myles Murray, will ring the opening bell of the Nasdaq Stockholm Exchange on 17 January 2024. Signatories attending the bell-ringing ceremony will include Jennifer Carroll MacNeill, Minister of State at the Department of Finance in Ireland; Barbara Jones, Irish Ambassador to Sweden; and Declan Caulfield, President of the Irish Chamber of Commerce in Sweden. For additional information, please contact: Myles Murray, CEO Phone: +353 86 887 4994 E-mail: myles@pmd-solutions.com; for general enquiries investor.relations@pmd-solutions.com The Company's Certified Adviser is Redeye. Information about PMD PMD develops and sells medical products for respiratory monitoring. Its primary product is RespiraSense™, a solution used for monitoring respiratory rate to detect deterioration of a patient's general condition early and to avoid preventable respiratory failure and adverse patient outcomes. RespiraSense™ is, to the PMD's knowledge, the world's only continuous, motion-tolerant respiratory rate monitor delivering class-leading reliability in measuring respiratory rate. PMD received FDA approval for RespiraSense™ in 2022. RespiraSense™ is a novel technology and today used in 25 hospitals across United Kingdom and Ireland. PMD seeks to continue increasing its market share in the United Kingdom, with Germany and the United States to follow with initial market access activities. The Company is listed on Nasdaq First North Growth Market. Link to prospectus For additional information, please contact: Myles Murray, CEO Phone: +353 86 887 4994 E-mail: myles@pmd-solutions.com & for general enquiries investor.relations@pmd-solutions.com The Company's Certified Adviser is Redeye. Promore Pharma in brief Promore Pharma is a biopharmaceutical company specialized in the development of locally administered first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. The company is listed on Nasdaq First North Growth Market. Attachments PMD - new name and ticker symbol; Irish Minister to attend bell-ringing ceremony SOURCE: Promore Pharma View the original press release on accesswire.com

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构